JPWO2020018620A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020018620A5 JPWO2020018620A5 JP2021502620A JP2021502620A JPWO2020018620A5 JP WO2020018620 A5 JPWO2020018620 A5 JP WO2020018620A5 JP 2021502620 A JP2021502620 A JP 2021502620A JP 2021502620 A JP2021502620 A JP 2021502620A JP WO2020018620 A5 JPWO2020018620 A5 JP WO2020018620A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally
- cells
- gene
- isolated
- car
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 claims 49
- 210000004027 cell Anatomy 0.000 claims 44
- 210000002865 immune cell Anatomy 0.000 claims 37
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 30
- 206010028980 Neoplasm Diseases 0.000 claims 17
- 238000000034 method Methods 0.000 claims 17
- 230000000694 effects Effects 0.000 claims 16
- 239000000126 substance Substances 0.000 claims 16
- 230000001939 inductive effect Effects 0.000 claims 15
- 201000011510 cancer Diseases 0.000 claims 13
- 230000004069 differentiation Effects 0.000 claims 13
- 238000000338 in vitro Methods 0.000 claims 13
- -1 CD31 Proteins 0.000 claims 12
- 108091033409 CRISPR Proteins 0.000 claims 12
- 108700002010 MHC class II transactivator Proteins 0.000 claims 12
- 102000004169 proteins and genes Human genes 0.000 claims 12
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 11
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 11
- 210000001744 T-lymphocyte Anatomy 0.000 claims 11
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims 11
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims 11
- 238000012258 culturing Methods 0.000 claims 11
- 102000004039 Caspase-9 Human genes 0.000 claims 10
- 108090000566 Caspase-9 Proteins 0.000 claims 10
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 10
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 10
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 10
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 10
- 230000004068 intracellular signaling Effects 0.000 claims 10
- 101100382122 Homo sapiens CIITA gene Proteins 0.000 claims 9
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 8
- 101150076800 B2M gene Proteins 0.000 claims 8
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 8
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 8
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 8
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 8
- 102000017578 LAG3 Human genes 0.000 claims 8
- 101150030213 Lag3 gene Proteins 0.000 claims 8
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 8
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 8
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 8
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 8
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical group NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 claims 8
- 229960004413 flucytosine Drugs 0.000 claims 8
- 210000001778 pluripotent stem cell Anatomy 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- 230000005847 immunogenicity Effects 0.000 claims 7
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 6
- 108700028369 Alleles Proteins 0.000 claims 6
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 6
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 6
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 6
- 101150028326 CD gene Proteins 0.000 claims 6
- 238000010354 CRISPR gene editing Methods 0.000 claims 6
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 238000006243 chemical reaction Methods 0.000 claims 6
- 230000008030 elimination Effects 0.000 claims 6
- 238000003379 elimination reaction Methods 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 230000002163 immunogen Effects 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 4
- 101001005269 Arabidopsis thaliana Ceramide synthase 1 LOH3 Proteins 0.000 claims 4
- 101001005312 Arabidopsis thaliana Ceramide synthase LOH1 Proteins 0.000 claims 4
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 4
- 102100028801 Calsyntenin-1 Human genes 0.000 claims 4
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 claims 4
- 108010080611 Cytosine Deaminase Proteins 0.000 claims 4
- 102000000311 Cytosine Deaminase Human genes 0.000 claims 4
- 101900095660 Escherichia coli Cytosine deaminase Proteins 0.000 claims 4
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 4
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 4
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims 4
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims 4
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims 4
- 101001051490 Homo sapiens Neural cell adhesion molecule L1 Proteins 0.000 claims 4
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims 4
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims 4
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims 4
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims 4
- 102100023123 Mucin-16 Human genes 0.000 claims 4
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 claims 4
- 241000700584 Simplexvirus Species 0.000 claims 4
- 101000668858 Spinacia oleracea 30S ribosomal protein S1, chloroplastic Proteins 0.000 claims 4
- 101000898746 Streptomyces clavuligerus Clavaminate synthase 1 Proteins 0.000 claims 4
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 4
- 102000006601 Thymidine Kinase Human genes 0.000 claims 4
- 108020004440 Thymidine kinase Proteins 0.000 claims 4
- 102000040856 WT1 Human genes 0.000 claims 4
- 108700020467 WT1 Proteins 0.000 claims 4
- 101150084041 WT1 gene Proteins 0.000 claims 4
- 239000012190 activator Substances 0.000 claims 4
- 239000000539 dimer Substances 0.000 claims 4
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical group O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims 4
- 229960002963 ganciclovir Drugs 0.000 claims 4
- 210000000822 natural killer cell Anatomy 0.000 claims 4
- 230000005487 simulated microgravity Effects 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 108010092408 Eosinophil Peroxidase Proteins 0.000 claims 3
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 3
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 claims 3
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 claims 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 3
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 3
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims 3
- 102000003812 Interleukin-15 Human genes 0.000 claims 3
- 108090000172 Interleukin-15 Proteins 0.000 claims 3
- 108010002350 Interleukin-2 Proteins 0.000 claims 3
- 102000000588 Interleukin-2 Human genes 0.000 claims 3
- 108010002386 Interleukin-3 Proteins 0.000 claims 3
- 102100039064 Interleukin-3 Human genes 0.000 claims 3
- 102000004889 Interleukin-6 Human genes 0.000 claims 3
- 108090001005 Interleukin-6 Proteins 0.000 claims 3
- 108010002586 Interleukin-7 Proteins 0.000 claims 3
- 102100021592 Interleukin-7 Human genes 0.000 claims 3
- 102100020880 Kit ligand Human genes 0.000 claims 3
- 101710177504 Kit ligand Proteins 0.000 claims 3
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 claims 3
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 claims 3
- 108700019146 Transgenes Proteins 0.000 claims 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 3
- 230000002068 genetic effect Effects 0.000 claims 3
- 239000003102 growth factor Substances 0.000 claims 3
- 102000001267 GSK3 Human genes 0.000 claims 2
- 108060006662 GSK3 Proteins 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 108091005735 TGF-beta receptors Proteins 0.000 claims 2
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 238000012239 gene modification Methods 0.000 claims 2
- 230000005017 genetic modification Effects 0.000 claims 2
- 235000013617 genetically modified food Nutrition 0.000 claims 2
- 230000002489 hematologic effect Effects 0.000 claims 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 238000007912 intraperitoneal administration Methods 0.000 claims 2
- 238000007913 intrathecal administration Methods 0.000 claims 2
- 230000002601 intratumoral effect Effects 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 claims 2
- 239000011435 rock Substances 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 101100437218 Homo sapiens B2M gene Proteins 0.000 claims 1
- 101100059527 Homo sapiens CD47 gene Proteins 0.000 claims 1
- 101100437231 Mus musculus B2m gene Proteins 0.000 claims 1
- 101100059528 Mus musculus Cd47 gene Proteins 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862698941P | 2018-07-17 | 2018-07-17 | |
| US62/698,941 | 2018-07-17 | ||
| PCT/US2019/042123 WO2020018620A1 (en) | 2018-07-17 | 2019-07-17 | Chimeric antigen receptor t cells derived from immunoengineered pluripotent stem cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021530999A JP2021530999A (ja) | 2021-11-18 |
| JPWO2020018620A5 true JPWO2020018620A5 (https=) | 2022-08-09 |
| JP2021530999A5 JP2021530999A5 (https=) | 2022-08-09 |
Family
ID=69164717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502620A Pending JP2021530999A (ja) | 2018-07-17 | 2019-07-17 | 免疫改変多能性幹細胞由来のキメラ抗原受容体ｔ細胞 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210308183A1 (https=) |
| EP (1) | EP3824075A4 (https=) |
| JP (1) | JP2021530999A (https=) |
| KR (1) | KR20210032449A (https=) |
| CN (1) | CN112639081A (https=) |
| AU (1) | AU2019305586B2 (https=) |
| BR (1) | BR112021000639A2 (https=) |
| CA (1) | CA3106022A1 (https=) |
| EA (1) | EA202190295A1 (https=) |
| IL (1) | IL279854A (https=) |
| MX (1) | MX2021000607A (https=) |
| SG (1) | SG11202100156UA (https=) |
| WO (1) | WO2020018620A1 (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12264189B2 (en) | 2018-10-31 | 2025-04-01 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| WO2020092736A1 (en) | 2018-10-31 | 2020-05-07 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| KR102776627B1 (ko) | 2019-05-06 | 2025-03-06 | 토마스 말콤 | 암 종양에 대한 맞춤화된 하이포면역 나노소포체 전달 시스템 |
| US11162079B2 (en) | 2019-05-10 | 2021-11-02 | The Regents Of The University Of California | Blood type O Rh-hypo-immunogenic pluripotent cells |
| WO2020231882A2 (en) | 2019-05-10 | 2020-11-19 | The Regents Of The University Of California | Modified pluripotent cells |
| AU2021207810A1 (en) * | 2020-01-13 | 2022-08-04 | Sana Biotechnology, Inc. | Modification of blood type antigens |
| MX2022011831A (es) * | 2020-03-25 | 2023-01-04 | Sana Biotechnology Inc | Células neurales hipoinmunogénicas para el tratamiento de trastornos y afecciones neurológicas. |
| CN115916962A (zh) * | 2020-04-27 | 2023-04-04 | 萨那生物技术股份有限公司 | 低免疫原性细胞的重复给药 |
| EP4149525A4 (en) * | 2020-05-15 | 2024-08-28 | Rxcell Inc. | HYPOIMMUNOGENIC CELLS AND THEIR USES IN IMMUNE RESPONSES |
| IL300516A (en) * | 2020-08-13 | 2023-04-01 | Sana Biotechnology Inc | Methods for treating susceptible patients with hypoimmunogenic cells, and related methods and compounds |
| US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| WO2022144632A1 (en) | 2020-12-30 | 2022-07-07 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into nk cells |
| CA3200509A1 (en) * | 2020-12-31 | 2022-07-07 | Sonja SCHREPFER | Methods and compositions for modulating car-t activity |
| US20250269022A1 (en) * | 2021-05-06 | 2025-08-28 | Mayo Foundation For Medical Education And Research | Assessing and treating cancer |
| BR112023024231A2 (pt) | 2021-05-19 | 2024-01-30 | Sana Biotechnology Inc | Células t primárias rhd negativas hipoimunogênicas |
| AU2022283291A1 (en) | 2021-05-27 | 2023-11-02 | Sana Biotechnology, Inc. | Hypoimmunogenic cells comprising engineered hla-e or hla-g |
| KR20240046319A (ko) | 2021-07-14 | 2024-04-08 | 사나 바이오테크놀로지, 인크. | 저면역원성 세포에서의 y 염색체-연결 항원의 변경된 발현 |
| MX2024000713A (es) * | 2021-07-16 | 2024-03-25 | Sana Biotechnology Inc | Vectores policistrónicos para terapias a base de células. |
| WO2023008918A1 (ko) * | 2021-07-28 | 2023-02-02 | 의료법인 성광의료재단 | B2m 유전자의 발현이 저해된 유전적으로 조작된 줄기세포 및 이의 이용방법 |
| TW202321435A (zh) | 2021-08-11 | 2023-06-01 | 美商薩那生物科技公司 | 用於改變低免疫原性細胞中之基因表現之可誘導系統 |
| KR20240073006A (ko) | 2021-08-11 | 2024-05-24 | 사나 바이오테크놀로지, 인크. | 동종이계 세포 요법을 위한 유전자 변형된 1차 세포 |
| WO2023019226A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy |
| AU2022325231A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions |
| JP2024535677A (ja) | 2021-08-11 | 2024-10-02 | サナ バイオテクノロジー，インコーポレイテッド | 即時血液媒介性炎症反応を減少させるための同種細胞療法を目的とした遺伝子改変細胞 |
| WO2023069790A1 (en) | 2021-10-22 | 2023-04-27 | Sana Biotechnology, Inc. | Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods |
| MX2024007528A (es) | 2021-12-23 | 2024-08-30 | Sana Biotechnology Inc | Linfocitos t del receptor de antígeno quimérico (car) para el tratamiento de enfermedades autoinmunitarias y métodos asociados. |
| KR20240142624A (ko) * | 2022-01-10 | 2024-09-30 | 사나 바이오테크놀로지, 인크. | 만능줄기세포에서 분화된 면역저하 베타세포 및 관련 용도 및 방법 |
| WO2023154578A1 (en) | 2022-02-14 | 2023-08-17 | Sana Biotechnology, Inc. | Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells |
| KR20240155390A (ko) | 2022-02-17 | 2024-10-28 | 사나 바이오테크놀로지, 인크. | 조작된 cd47 단백질 및 이의 용도 |
| CN119213117A (zh) * | 2022-04-07 | 2024-12-27 | 菲特治疗公司 | 用于同种异体细胞疗法的参与免疫识别途径的隐形策略 |
| EP4504914A4 (en) | 2022-04-08 | 2026-04-29 | Fate Therapeutics Inc | Cells having solid tumor targeting backbone and use thereof |
| CA3247010A1 (en) | 2022-04-08 | 2023-10-12 | Ono Pharmaceutical Co., Ltd. | CHIMERIC ANTIGEN RECEPTOR FOR TUMOR TARGETING |
| CA3254552A1 (en) * | 2022-04-28 | 2023-11-02 | Allogene Therapeutics Inc. | METHODS FOR ANALYZING DONOR CELLS |
| JP2025518125A (ja) * | 2022-05-25 | 2025-06-12 | マルコルム，トーマス | 生体模倣型ナノ小胞を作製するための低免疫原性細胞 |
| WO2023230533A1 (en) * | 2022-05-25 | 2023-11-30 | Jasper Therapeutics, Inc. | Modified stem cell compositions and methods for use |
| EP4547825A1 (en) | 2022-07-01 | 2025-05-07 | Novo Nordisk A/S | Enhancing neuronal differentiation of ventral midbrain neural progenitor cells |
| WO2024097315A2 (en) * | 2022-11-02 | 2024-05-10 | Sana Biotechnology, Inc. | Cell therapy products and methods for producing same |
| CN118207165B (zh) * | 2022-12-07 | 2026-03-20 | 士泽生物医药（苏州）有限公司 | 一种表达stc1的通用型细胞及其制备方法 |
| CN115612673A (zh) * | 2022-12-14 | 2023-01-17 | 卡瑞济(北京)生命科技有限公司 | 一种改善car-t细胞群的持久性的方法 |
| WO2024183750A1 (en) * | 2023-03-07 | 2024-09-12 | Qihan Hong Kong Limited | A novel immune cell and use thereof for treating diseases |
| WO2025003393A1 (en) | 2023-06-30 | 2025-01-02 | Novo Nordisk A/S | Enhancing neuronal differentiation of neural progenitor cells |
| WO2025029826A1 (en) * | 2023-07-31 | 2025-02-06 | Seraxis, Inc. | Modified therapeutics cells and methods relating to the same |
| AU2024328949A1 (en) | 2023-08-23 | 2026-03-12 | Sana Biotechnology, Inc. | Modified cd47 proteins and their uses |
| WO2025096757A1 (en) | 2023-11-01 | 2025-05-08 | Sana Biotechnology, Inc. | Hypoimmunogenic cd22-targeted car t cells for the treatment of relapsed and/or refractory b cell lymphomas |
| CN117737130A (zh) * | 2023-12-21 | 2024-03-22 | 南京康和细胞基因工程研究院有限公司 | 一种提高通用型car-t细胞产量和活性的制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001297880B2 (en) * | 2000-11-30 | 2007-05-31 | Stemron Inc. | Isolated homozygous stem cells differentiated cells derived therefrom and materials and methods for making and using same |
| AU2014248119B2 (en) * | 2013-04-03 | 2019-06-20 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted T-cells derived from pluripotent stem cells |
| EP3134515B1 (en) * | 2014-04-24 | 2019-03-27 | Board of Regents, The University of Texas System | Application of induced pluripotent stem cells to generate adoptive cell therapy products |
| EP3294342A4 (en) * | 2015-05-08 | 2018-11-07 | President and Fellows of Harvard College | Universal donor stem cells and related methods |
| GB201518136D0 (en) * | 2015-10-14 | 2015-11-25 | Glaxosmithkline Ip Dev Ltd | Novel chimeric antigen receptors |
| JP6928604B2 (ja) * | 2015-11-04 | 2021-09-01 | フェイト セラピューティクス，インコーポレイテッド | 万能性細胞のゲノム改変 |
| CN110177869A (zh) * | 2017-01-13 | 2019-08-27 | 加利福尼亚大学董事会 | 免疫改造的多能细胞 |
| US20200109364A1 (en) * | 2018-05-31 | 2020-04-09 | Washington University | Methods for genome-editing and activation of cells |
-
2019
- 2019-07-17 US US17/260,222 patent/US20210308183A1/en active Pending
- 2019-07-17 JP JP2021502620A patent/JP2021530999A/ja active Pending
- 2019-07-17 CN CN201980056559.7A patent/CN112639081A/zh active Pending
- 2019-07-17 AU AU2019305586A patent/AU2019305586B2/en active Active
- 2019-07-17 SG SG11202100156UA patent/SG11202100156UA/en unknown
- 2019-07-17 MX MX2021000607A patent/MX2021000607A/es unknown
- 2019-07-17 CA CA3106022A patent/CA3106022A1/en active Pending
- 2019-07-17 KR KR1020217004389A patent/KR20210032449A/ko not_active Ceased
- 2019-07-17 EP EP19838516.3A patent/EP3824075A4/en active Pending
- 2019-07-17 WO PCT/US2019/042123 patent/WO2020018620A1/en not_active Ceased
- 2019-07-17 BR BR112021000639-7A patent/BR112021000639A2/pt unknown
- 2019-07-17 EA EA202190295A patent/EA202190295A1/ru unknown
-
2020
- 2020-12-30 IL IL279854A patent/IL279854A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020018620A5 (https=) | ||
| JP2021530999A5 (https=) | ||
| JP7093385B2 (ja) | 薬物制御による導入遺伝子の発現 | |
| JP7008350B2 (ja) | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 | |
| AU2023233207A1 (en) | Chimeric antigen receptors (CARs), compositions and methods of use thereof | |
| Schmitt et al. | T cell receptor gene therapy for cancer | |
| Rossig et al. | Genetic modification of T lymphocytes for adoptive immunotherapy | |
| KR102228828B1 (ko) | 동종이형 이식에 양립성인 t-세포들을 만들어내는 방법 | |
| Morgan et al. | Adoptive cell therapy: genetic modification to redirect effector cell specificity | |
| US10647997B2 (en) | Modified effector cell (or chimeric receptor) for treating disialoganglioside GD2-expressing neoplasia | |
| US20250242024A1 (en) | Multipartite receptor and signaling complexes | |
| Engels et al. | Redirecting human T lymphocytes toward renal cell carcinoma specificity by retroviral transfer of T cell receptor genes | |
| JP2024036482A (ja) | Ｄａｒｉｃインターロイキン受容体 | |
| JP2022513460A (ja) | 二量体形成剤調節性免疫受容体複合体 | |
| JP2022512475A (ja) | 二量体化剤調節免疫受容体複合体 | |
| KR20200108285A (ko) | Nkg2d daric 수용체 | |
| CN113660942A (zh) | 嵌合细胞因子受体 | |
| CN114514247A (zh) | Car-cd123载体及其用途 | |
| CN113366109A (zh) | 细胞特异性转录调控序列及其用途 | |
| KR20230090367A (ko) | 변형된 불변 cd3 이뮤노글로불린 슈퍼패밀리 쇄 유전자좌로부터 키메라 수용체를 발현하는 세포 및 관련 폴리뉴클레오티드 및 방법 | |
| US20230277622A1 (en) | CHIMERIC ANTIGEN RECEPTORS (CARs) COMPOSITIONS AND METHODS THEREOF | |
| KR20250152083A (ko) | 1차 면역 세포를 생성하는 방법 | |
| KR20230074505A (ko) | 원하는 특이성을 갖는 이펙터 세포의 제조 방법 | |
| WO2021202581A1 (en) | Engineered immune cells for adoptive cell therapy | |
| CN116426484A (zh) | 嵌合抗原受体t细胞群、组合物及其用途 |